个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Li, Y.[1] * ; Zhou, A.[2] ; Liu, S.[3] ; He, M.[4] ; Chen, K-N.[5] ; Tian, Z.[6] ; Chen, H.[7] ; Tian, H.[8] ; Yu, Y.[9] ; Qu, W.[2] ; Xue, L.[10] ; Wang, S.[9] ; Bie, F.[1] ; Zhou, B.[1] ; Huang, H. Y.[9] ; Fang, Y.[11] ; Li, B.[12] ; Dai, X.[12] ; Gao, S.[1] ; He, J.[1] ;
机构： [1]Thoracic Surgery, National Cancer Center/National Clinical Center for Cancer/CancerHospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Bejing, China [2]Medical Oncology, National Cancer Center/National Clinical Center forCancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking UnionMedical College, Bejing, China [3]Thoracic Surgery, Fujian Provincial Cancer Hospital,Fuzhou, China [4]Thoracic Surgery, Fourth Hospital of Hebei Medical University,Changan, China [5]Thoracic Surgery, Peking University School of Oncology, BeijingCancer Hospital, Beijing, China [6]Thoracic Surgery, The Fourth Hospital of HebeiMedical University - North Gate, Shijiazhuang, China [7]Thoracic Surgery, Fudan UniversityCancer Hospital, Shanghai, China [8]Department of Thoracic Surgery, QiluHospital of Shandong University, Jinan, China [9]Clinical Trial Center, National CancerCenter/National Clinical Center for Cancer/Cancer Hospital,Chinese Academy ofMedical Sciences and Peking Union Medical College, Bejing, China [10]Pathology, ChineseAcademy of Medical Sciences and Peking Union Medical College - NationalCancer Center, Cancer Hospital, Beijing, China [11]PET-CT center, National CancerCenter/National Clinical Center for Cancer/Cancer Hospital,Chinese Academy ofMedical Sciences and Peking Union Medical College, Bejing, China [12]Sponsor, Lee’sPharmaceutical Limited, Shenzhen, China
出处：
ISSN：
基金：
Lee's Pharmaceutical Limited
语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2022]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Thoracic Surgery, National Cancer Center/National Clinical Center for Cancer/CancerHospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Bejing, China
推荐引用方式(GB/T 7714)：
Li Y.,Zhou A.,Liu S.,et al.Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study[J].ANNALS OF ONCOLOGY.2022,33(7):S1101-S1101.
APA：
Li, Y.,Zhou, A.,Liu, S.,He, M.,Chen, K-N....&He, J..(2022).Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study.ANNALS OF ONCOLOGY,33,(7)
MLA：
Li, Y.,et al."Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study".ANNALS OF ONCOLOGY 33..7(2022):S1101-S1101

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号